Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProVanc
2023-509003-32-00Phase 4Completed
- Sponsor
- Tartu University Hospital
- Start
- Jan 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vancomycin in bacterial disease, sponsored by Tartu University Hospital. Started Jan 2024; status: completed.
02
Drugs
vancomycin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2023-509003-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509003-32-00.